Research progress of GH/IGF-1 axis in metabolic-associated fatty liver disease
Metabolic-associated fatty liver disease(MAFLD)affects about 1/4 of adults and is one of the main risks for the development of cirrhosis and liver cancer.Currently,there is no specific drug treatment available.Growth hormone(GH)inhibits liver fat production,while insulin-like growth factor 1(IGF-1)inhibits liver inflammation and fibrosis;disruption of gut-liver axis is an important factor in the progression of MAFLD,and GH/IGF-1 axis can regulate gut-liver axis to delay the progression of MAFLD,demonstrating great potential for treating MAFLD;insulin-like growth factor binding protein(IGFBP),as a secreted protein,is gradually being revealed in the development of MAFLD.This article reviews the mechanism of action of GH/IGF-1 axis and IGFBP 1-3 on MAFLD,and explores the feasibility of treating MAFLD from the perspective of supplementing GH/IGF-1.
NETL
NSTL
万方数据
